According to a recent research report titled ” Biosimilar Monoclonal Antibody Market (By Type: Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others; By Indication: Oncology, Autoimmune diseases, Others; By End User: Hospitals, Cancer treatment centers, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032″ published by Precedence Research, the global biosimilar monoclonal antibody market size is projected to touch around USD 69 billion by 2032 and growing at a CAGR of 23.2% over the forecast period 2023 to 2032. This comprehensive study examines various factors and their impact on the growth of the biosimilar monoclonal antibody market.
Key Takeaway
- North America contributed more than 35% of revenue share in 2022.
- Asia-Pacific is expected to expand at the biggest CAGR of 8.3% between 2023 and 2032.
- By Type, the infliximab segment has held the largest market share of 32% in 2022.
- By Type, the adalimumab segment is anticipated to grow at a remarkable CAGR of 24.7% between 2023 and 2032.
- By Indication, the oncology segment captured more than 44% of revenue share in 2022.
- By Indication, the autoimmune diseases segment is projected to expand at the fastest CAGR over the projected period.
- By End-user, the hospital segment led the market with the largest market share of 49% in 2022.
- By End-user, the others segment is anticipated to grow at the fastest CAGR over the projected period.
The report primarily focuses on the volume and value of the biosimilar monoclonal antibody market at the global, regional, and company levels. At the global level, the report analyzes historical data and future prospects to present an overview of the overall market size. Regionally, the study emphasizes key regions such as North America, Europe, the Middle East & Africa, Latin America, and others.
Furthermore, the research report provides specific segmentations based on regions (countries), companies, and all market segments. This analysis offers insights into the growth and revenue trends during the historical period of 2017 to 2032, as well as the projected period. By understanding these segments, it becomes possible to identify the significance of different factors that contribute to market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3400
The research also highlights significant progressions in both organic and inorganic growth strategies within the global biosimilar monoclonal antibody market. Numerous companies are placing emphasis on new product launches, gaining product approvals, and implementing various business expansion tactics. Moreover, the report presents detailed profiles of firms operating in the biosimilar monoclonal antibody market, along with their respective market strategies. Additionally, the study concentrates on prominent industry participants, furnishing details such as company profiles, product offerings, financial updates, and noteworthy advancements.
Biosimilar Monoclonal Antibody Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 23.2% |
| Market Size in 2023 | USD 10.55 Billion |
| Market Size by 2032 | USD 69 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Type, By Indication, and By End User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Also read: Risk Analytics Market Size to Record US$ 79.24 Billion by 2032
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.
Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
Biosimilar Monoclonal Antibody Market Opportunities:
The Biosimilar Monoclonal Antibody Market presents a promising landscape with several opportunities for growth and development. One significant advantage lies in the potential cost savings for healthcare systems and patients. Biosimilars offer a more affordable alternative to originator monoclonal antibodies, making advanced biologic treatments more accessible.
Moreover, the increasing prevalence of chronic diseases creates a substantial demand for effective and affordable treatment options. Biosimilar monoclonal antibodies have the potential to address this need by providing comparable therapeutic outcomes at a lower cost, thus expanding patient access to critical therapies.
The evolving regulatory landscape is also creating opportunities for companies in this market. As regulatory agencies streamline and clarify guidelines for biosimilar development and approval, it facilitates a more predictable and efficient pathway for manufacturers to bring these products to market, encouraging investment and innovation.
Biosimilar Monoclonal Antibody Market Challenges:
However, navigating the Biosimilar Monoclonal Antibody Market comes with its set of challenges. One primary hurdle is the complexity of manufacturing and ensuring the similarity of biosimilars to their reference products. Achieving the required level of similarity involves overcoming scientific and technical challenges, demanding substantial investments in research and development.
Another challenge lies in the market competition. The presence of multiple players vying for a share of the market intensifies the competition, requiring companies to differentiate their products and establish a robust market presence.
Market Key Players
The report incorporates company profiles of key players in the market. These profiles encompass vital information such as product portfolio, key strategies, and a comprehensive SWOT analysis for each player. Additionally, the report presents a matrix illustrating the presence of each prominent player, enabling readers to gain actionable insights. This facilitates a thoughtful assessment of the market status and aids in predicting the level of competition in the biosimilar monoclonal antibody market.
Some of the prominent players in the biosimilar monoclonal antibody market include
- Roche
- Novartis
- Pfizer
- Samsung Bioepis
- Amgen
- Mylan
- Teva Pharmaceutical Industries
- Biogen
- Celltrion
- Fresenius Kabi
- Sandoz
- Boehringer Ingelheim
- Merck
- Amneal Pharmaceuticals
- Biocon
Market Segmentations
By Type
- Adalimumab
- Bevacizumab
- Infliximab
- Rituximab
- Trastuzumab
- Others
By Indication
- Oncology
- Autoimmune diseases
- Others
By End User
- Hospitals
- Cancer treatment centers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Table of Content:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Biosimilar Monoclonal Antibody Market
5.1. COVID-19 Landscape: Biosimilar Monoclonal Antibody Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Biosimilar Monoclonal Antibody Market, By Type
8.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Type, 2023-2032
8.1.1 Adalimumab
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Bevacizumab
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Infliximab
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Rituximab
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Trastuzumab
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Biosimilar Monoclonal Antibody Market, By Indication
9.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Indication, 2023-2032
9.1.1. Oncology
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Autoimmune diseases
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Biosimilar Monoclonal Antibody Market, By End User
10.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by End User, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Cancer treatment centers
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Biosimilar Monoclonal Antibody Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)
Chapter 12. Company Profiles
12.1. Roche
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Samsung Bioepis
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Amgen
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Mylan
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Teva Pharmaceutical Industries
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Biogen
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Celltrion
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Fresenius Kabi
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Why should you invest in this report?
This report presents a compelling investment opportunity for those interested in the global biosimilar monoclonal antibody market. It serves as an extensive and informative guide, offering clear insights into this niche market. By delving into the report, you will gain a comprehensive understanding of the various major application areas for biosimilar monoclonal antibody. Furthermore, it provides crucial information about the key regions worldwide that are expected to experience substantial growth within the forecast period of 2023-2030. Armed with this knowledge, you can strategically plan your market entry approaches.
Moreover, this report offers a deep analysis of the competitive landscape, equipping you with valuable insights into the level of competition prevalent in this highly competitive market. If you are already an established player, it will enable you to assess the strategies employed by your competitors, allowing you to stay ahead as market leaders. For newcomers entering this market, the extensive data provided in this report is invaluable, providing a solid foundation for informed decision-making.
Some of the key questions answered in this report:
- What is the size of the overall Biosimilar monoclonal antibody market and its segments?
- What are the key segments and sub-segments in the market?
- What are the key drivers, restraints, opportunities and challenges of the Biosimilar monoclonal antibody market and how they are expected to impact the market?
- What are the attractive investment opportunities within the Biosimilar monoclonal antibody market?
- What is the Biosimilar monoclonal antibody market size at the regional and country-level?
- Who are the key market players and their key competitors?
- What are the strategies for growth adopted by the key players in Biosimilar monoclonal antibody market?
- What are the recent trends in Biosimilar monoclonal antibody market? (M&A, partnerships, new product developments, expansions)?
- What are the challenges to the Biosimilar monoclonal antibody market growth?
- What are the key market trends impacting the growth of Biosimilar monoclonal antibody market?
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
